AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - nature.com
We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …
被引用次数：95 相关文章

[引用][C] AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P FROST - Oncogene, 2007 - cir.nii.ac.jp
[PDF] academia.edu

[PDF][PDF] AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - academia.edu
Mammalian target of rapamycin (mTOR) inhibitors have demonstrated potential in preclinical
studies as effective agents against multiple myeloma (MM)(Tu et al., 2000; Hideshima et al …

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2006 - europepmc.org
We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …
[PDF] researchgate.net

[PDF][PDF] AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - researchgate.net
Mammalian target of rapamycin (mTOR) inhibitors have demonstrated potential in preclinical
studies as effective agents against multiple myeloma (MM)(Tu et al., 2000; Hideshima et al …

[引用][C] AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P FROST, Y SHI, B HOANG… - Oncogene …, 2007 - pascal-francis.inist.fr
AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF
expression in multiple myeloma cells CNRS Inist Pascal-Francis CNRS Pascal and Francis …

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - go.gale.com
We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - search.ebscohost.com
We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - pubmed.ncbi.nlm.nih.gov
We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.

P Frost, Y Shi, B Hoang, A Lichtenstein - Oncogene, 2007 - search.ebscohost.com
We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …